United Therapeutics (UTHR) net income: $1.3B
United Therapeutics reported a net income of $1.3B for the year ended Dec 31, 2025, up 11.7% from $1.2B a year earlier.
From United Therapeutics's filings with the SEC · Read the filing · UTHR stock page
United Therapeutics net income by year
#296 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | $1.3B | +12% |
| Dec 31, 2024 | $1.2B | +21% |
| Dec 31, 2023 | $985M | +35% |
| Dec 31, 2022 | $727M | +53% |
| Dec 31, 2021 | $476M | – |
Net income of similar companies
Companies in the same industry as United Therapeutics, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Vertex Pharmaceuticals Inc / Ma | $4B | Dec 31, 2025 |
| Zoetis | $2.7B | Dec 31, 2025 |
| TEVA Pharmaceutical Industries | $1.4B | Dec 31, 2025 |
| United Therapeutics | $1.3B | Dec 31, 2025 |
| Royalty Pharma | $771M | Dec 31, 2025 |
| PTC Therapeutics | $683M | Dec 31, 2025 |
| HUTCHMED (China) | $457M | Dec 31, 2025 |
Questions and answers
What is United Therapeutics's net income?
United Therapeutics reported a net income of $1.3B for the year ended Dec 31, 2025, up 11.7% from $1.2B a year earlier.
Numbers as reported in United Therapeutics's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology